And so that’s the profile that we’re going for long term. From an M&A standpoint, our first priority is that revenue growth and that diversification of the company into faster-growth markets. That may come with some near-term dilution, but we’re also going to be very conscious about driving P&L discipline and looking for accretion in a reasonable amount of time, let’s say, within the first 2 years. So that’s how we think about M&A. The priority is going to be about accelerating the overall company’s growth.
Operator: We’ll go next to Pito Chickering with Deutsche Bank.
Philip Chickering: Can we touch more into S.E.T. You talked about strength in 3 focus areas, as process of supply challenges. What were those issues? Are they fixed at this point? And how should we be modeling S.E.T. in the back half of the year? And if the supply tunnels are fixed, should we think about bolus in the third quarter?
Suketu Upadhyay: Yes. So a couple of things that inside the second quarter on S.E.T. One, we continue to work through some of the reimbursement changes in our Restorative Therapies business that we talked about a year ago. We believe we’ve now sunsetted those. So those shouldn’t be a challenge as we move into Q3 and Q4, the rest of the year. However, we did see some pretty acute supply issues, especially in our Sports business and to a lesser extent, Trauma. That muted growth. But underneath that, our priority areas of Sports, Upper Extremities and CMFT all performed incredibly well. And so we’re happy with the continued progress and momentum we’re making in those businesses. We do expect an inflection in the back half of the year for those — for the S.E.T. category as a whole to rebound. It’s likely going to be stronger in the fourth quarter as we continue to work through the fluid situation on supply in the third quarter.
Philip Chickering: Okay. Great. And then in the script, you talked about Russia getting growth. Can you walk us through a Russia could impact growth at this point and quantify the revenues and raw materials exposed to Russia?
Suketu Upadhyay: Sure. So overall, Russia is less than 1% of total sales on a full year basis. We became aware at the end of — towards the end of the second quarter, that new and unexpected sanctions were being placed on certain medical device products. Our products sell into that category. So we basically have to go back and reapply for licensing against all of our products. We don’t think that, that’s going to be a governor in perpetuity, but at least for the third quarter, it’s going to create a bit of a headwind potentially a little bit into Q4 worst case. We think that, that headwind is roughly about 50 basis points in the back half of the year. And again, most of that will be felt in the third quarter. From a raw materials exposure, I think the biggest area, and we’ve talked about this at length — our titanium supplies coming out of Russia have been relatively stable.
That’s a good sign. But we also took the additional measure at the end of ’22 to create some redundancy and to find alternate suppliers, multiple suppliers outside of Russia. So we feel good about our titanium supplies.
Operator: We’ll go next to Jeff Johnson with Baird.
Jeffrey Johnson: Kind of, I guess, we’re ticking through all the segments here. So maybe if we just look at the Other segment, the 6% growth that was at least a nice step-up from what we’ve seen kind of on a trailing 12-month basis. Maybe any insights there what drove that and just kind of how we’re seeing mix between leasing contracts and/or outright purchases on ROSA?
